RxDoctor Payments Data

Kevin Liebmann

Nurse Practitioner · Princeton, NJNPI 1154939064

Payments from drug & device makers

$2,494in general payments, 2019–2025

Across 120 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$329
  • Johnson & Johnson$244
  • E.r. Squibb & Sons, L.L.C.$224
  • Regeneron Healthcare Solutions, Inc.$221
  • AbbVie$187
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$180
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,22689%
  • Education$26811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,494 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$260,593
Medicare patients
643
Services billed
3,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$67,169
Clobetasol Propionate76$2,266
Fluorouracil33$2,022
Ketoconazole112$1,859
Metronidazole36$1,166
Tretinoin12$1,095
Triamcinolone Acetonide137$1,029
Gentamicin Sulfate32$779
Mupirocin126$672
Doxycycline Hyclate31$655
Minoxidil17$266
Hydrocortisone55$212
Nystatin17$166
ValacyclovirValacyclovir Hcl13$158
CiclopiroxCiclopirox Olamine12$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$28$67,16914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →